Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439959 · ClinicalTrials.gov registry record · Phase 1
Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00439959 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 48 participants.
The verdict
NCT00439959, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study represents the first administration of GSK625433 in humans. The study is designed to evaluate initial safety and tolerability in healthy adults as well as anti-viral activity in Hepatitis C(HVC) infected adults. The way the human body processes GSK625433 will also be investigated.
Interventions
- DRUG GSK625433/placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439959
The ClinicalTrials.gov registry entry for NCT00439959 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK625433/placebo is the first listed.
NCT00439959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00439959 about?
NCT00439959 is a clinical study titled "Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults". This study represents the first administration of GSK625433 in humans. The study is designed to evaluate initial safety and tolerability in healthy adults as well as anti-viral activity in Hepatitis C(HVC) infected adults. The way the human body processes GSK625433 will also be investigated.
What is the current status of trial NCT00439959?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2006-10. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00439959?
The interventions under investigation include: GSK625433/placebo (DRUG).
Who is sponsoring clinical trial NCT00439959?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.